Johnson & Johnson JNJ

$276.32 +10.15 (3.81%)

Valuation

Market cap
640,753,792,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.40
P/E (forward)
24.34
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,622,100
Avg volume
7,133,516
Day's range
$267.67 – $277.35
Shares out
2,407,310,000
Stochastic %K
71%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

GTA_Terminal Nov 5, 12:36 AM
Something's going on under the surface in $JNJ: off-exchange volume ran well above normal, about 1.6x. Price didn't move much, which is what you'd expect if somebody big is building or unwinding a position quietly. The options side leaned calls the same day. Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-activity-unusual-off-exchange-trading-in-johnson-johnson-jnj?utm_source=stocktwits&utm_medium=social
0 replies
Estimize Nov 5, 12:09 AM
Wall St is expecting 2.91 EPS for $JNJ Q4 [Reporting 01/26 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 replies
chursinow62 Nov 4, 9:25 PM
$JNJ Load lots of stock changing news coming .Blue Wave
0 replies
SellasgpsCurativeBAT11 Nov 4, 8:26 PM
$PFE $SLS $JNJ Keep an eye on Dr. Bourla in the coming days. Things are going to move very quickly moving forward. ✌️🙏❤️‍🩹
1 replies
JFais Nov 4, 7:54 PM
$SNDX - sizing down (partial profits) ended up being the right decision for me Good example of customizable Tier system (introduced in Weekly Recap) helping, as I have to justify sizing for each position in relation to newsflow & r/r Menin space evolving quickly (full notes in Chat on $JNJ, $KURA & Sumitomo along with group discussion on future implications)
0 replies
NeverFadeTheOracle Nov 4, 5:55 PM
$JNJ Blood cancer test $KURA catching strays
0 replies
CrazyCajun7 Nov 4, 5:20 PM 0 replies
Valueforall Nov 4, 3:10 PM
$KURA 1. Threat to Frontline Triplet Dominance The market value for the Menin class isn't in relapsed/refractory salvage; it's in frontline combination therapy (Menin + Venetoclax + Azacitidine). Kura ($KURA) with ziftomenib (Komzifti) and Syndax ($SNDX) with revumenib (Revuforj) were assumed to hold an insurmountable 18–24 month commercial head start. J&J's impressive frontline triplet numbers (90% ORR / 75% cCR) prove that a Big Pharma balance sheet ($JNJ) has a best-in-class contender advancing rapidly into Phase 3 (cAMeLot-2 study).
3 replies